The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany

Abstract Background We analysed the impact of clinical study design for oncological pharmaceuticals on the subsequent price negotiations after early benefit assessment between pharmaceutical companies and the German National Association of Statutory Health Insurance Funds. The analysis was conducted...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: C. M. Dintsios, I. Beinhauer
Format: Artigo
Jezik:Inglês
Izdano: BMC 2020-03-01
Serija:Health Economics Review
Teme:
Study design
Negotiated prices
Oncological drugs
Pharmaceutical companies
Payers
German statutory health insurance
Online pristup:http://link.springer.com/article/10.1186/s13561-020-00263-2
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items